Filing Details
- Accession Number:
- 0000914475-14-000088
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-15 19:22:33
- Reporting Period:
- 2014-12-12
- Filing Date:
- 2014-12-15
- Accepted Time:
- 2014-12-15 19:22:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1567160 | Kyle Gano | Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego CA 92130 | Chief Business Dev Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-12-12 | 4,043 | $5.00 | 27,781 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-12-12 | 4,043 | $22.50 | 23,738 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Incentive Stock Option | Disposition | 2014-12-12 | 4,043 | $5.00 | 4,043 | $5.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
4,957 | 2015-03-12 | No | 4 | M | Direct |
Footnotes
- The option was granted March 12, 2008 and vested in 36 equal monthly installments beginning April 12, 2008.
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.